Multiple myeloma patients get continued access to isatuximab in safety extension study
NCT ID NCT05669989
First seen Jun 26, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study offers continued treatment with isatuximab (a targeted antibody) to adults with multiple myeloma who were already benefiting from it in earlier trials. About 70 participants will receive the drug, possibly combined with other medications, to monitor long-term safety. The goal is to ensure patients can keep accessing a therapy that works for them.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Isatuximab (with possible cemiplimab, dexamethasone, lenalidomide, or pomalidomide)
- What this could lead to
- If successful, this study could show that long-term isatuximab treatment is safe and continues to control multiple myeloma, offering ongoing benefit to patients.
- What could go wrong
- This is a small, open-label extension study (70 participants) focused on safety, not on proving new effectiveness. It may not show clear long-term benefits or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Mae de Deus- Site Number : 0760003
Porto Alegre, Rio Grande do Sul, 90880-480, Brazil
-
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo - HCFMUSP- Site Number : 0760002
São Paulo, São Paulo, 05403-010, Brazil
-
Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760001
Rio de Janeiro, 22775-001, Brazil
-
Investigational Site Number : 0360001
Saint Leonards, New South Wales, 2065, Australia
-
Investigational Site Number : 0360002
Richmond, Victoria, 3121, Australia
-
Investigational Site Number : 0360003
Wollongong, New South Wales, 2500, Australia
-
Investigational Site Number : 0360004
Melbourne, Victoria, 3065, Australia
-
Investigational Site Number : 0360005
Melbourne, Victoria, 3084, Australia
-
Investigational Site Number : 0360006
Blacktown, New South Wales, 2148, Australia
-
Investigational Site Number : 1520001
Temuco, 4780000, Chile
-
Investigational Site Number : 1560001
Tianjin, 300020, China
-
Investigational Site Number : 1580001
Taichung, 404, Taiwan
-
Investigational Site Number : 2030001
Prague, 128 08, Czechia
-
Investigational Site Number : 2030002
Brno, 625 00, Czechia
-
Investigational Site Number : 2030003
Ostrava, 708 52, Czechia
-
Investigational Site Number : 2460001
Helsinki, 00029, Finland
-
Investigational Site Number : 2500002
Nantes, 44093, France
-
Investigational Site Number : 3000001
Pátrai, 265 04, Greece
-
Investigational Site Number : 3000003
Athens, 115 28, Greece
-
Investigational Site Number : 3000004
Athens, 106 76, Greece
-
Investigational Site Number : 3800002
Torino, 10126, Italy
-
Investigational Site Number : 3920001
Okayama, 701-1192, Japan
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 06591, South Korea
-
Investigational Site Number : 5540001
Wellington, 6021, New Zealand
-
Investigational Site Number : 5540002
Auckland, 2025, New Zealand
-
Investigational Site Number : 6430001
Moscow, 125284, Russia
-
Investigational Site Number : 6430002
Kirov, 610027, Russia
-
Investigational Site Number : 7240001
Pamplona, Navarre, 31008, Spain
-
Investigational Site Number : 7240002
Salamanca, 37007, Spain
-
Investigational Site Number : 7240003
Madrid, 28041, Spain
-
Investigational Site Number : 7240004
Santander, Cantabria, 39008, Spain
-
Investigational Site Number : 7240005
Badalona, Catalunya [Cataluña], 08916, Spain
-
Investigational Site Number : 7240006
Seville, Andalusia, 41013, Spain
-
Investigational Site Number : 7241001
Madrid, Madrid, Comunidad de, 28027, Spain
-
Investigational Site Number : 7520004
Luleå, 971 80, Sweden
-
Washington University- Site Number : 8400001
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer drug's real-world performance match clinical trial results?
- Can a maintenance drug keep myeloma at bay?
- New hope for frail myeloma patients: phase III trial tests smarter drug combos
- Could a tiny dose of radiation ease myeloma bone pain?
- Could a common allergy pill ease bone pain in myeloma treatment?
- New vaccine aims to train immune system against myeloma